Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...

Sandoz is one of the largest biosimilars players in the world and we believe it is well-positioned to benefit from the fast pace of growth the market is expected to enjoy over the next decade. Sandoz ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesMEDIA RELEASEFY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in ...

Biosimilars drove this increase with a 30% CER rise, while generics grew 2% CER. Core EBITDA for the second half was $40 million above consensus, with a full-year margin of 20.1%, exceeding the 19.7% ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE FY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in constant currencies (+7% in USD); Q4 net sales of ...

Among the biosimilar switchers, the most commonly used products were Hulio (37.7%), Hadlima (27.6%), Hyrimoz (21.1%), Idacio (11.8%), and Amgevita (1.74%). The mean (SD) duration of ADA continuation ...

The company ranks number one in biosimilars globally and across key markets in Europe. The commercial availability of Pyzchiva, which builds on the US launch of Hyrimoz in July 2023, marks an ...

Monday said that Pyzchiva (ustekinumab-ttwe) is now commercially available to patients across the U.S. Developed by Samsung Bioepis Co., and commercialized by Sandoz, Pyzchiva has been approved by the ...

The commercial availability of Pyzchiva®, which builds on the US launch of Hyrimoz® in July 2023, marks an important step in the Sandoz strategic ambition to become number one in biosimilars in ...

The commercial availability of Pyzchiva®, which builds on the US launch of Hyrimoz® in July 2023, marks an important step in the Sandoz strategic ambition to become number one in biosimilars in the US ...